



**Resonance Health Ltd**  
**ASX / Media Release**  
**3 April 2013**

---

## **FerriScan contracted for European Union funded drug trial**

Resonance Health has signed a two-year agreement to provide image analysis services for a European Union funded clinical trial of an iron chelation therapy. The project is called Deferiprone Evaluation in Paediatrics (DEEP). The value of this contract for the Company is in excess of AUD\$200,000.

Resonance Health will provide FerriScan liver iron concentration measurements and cardiac T2\* (cardiac iron overload) measurements to approximately 15 MRI centres in a number of countries in Europe and North Africa. Patients enrolled in the study suffer from inherited blood disorders that require them to have regular blood transfusions from a very young age which can result in iron overload.

The European organisation commissioned to run the study conducted an evaluation of technologies available for the measurement of iron overload and concluded that: *"R2 MRI [FerriScan] showed a better accuracy compared to other MRI technique and can be used routinely in the liver iron measurement."*

Resonance Health is now contracted to provide FerriScan services in clinical trials of three different iron chelation drugs. The funding of FerriScan by the European Union for the DEEP project further consolidates FerriScan's reputation as the gold standard test for the measurement of liver iron overload. The strong demand for FerriScan in clinical trials continues to drive growth in its use for the routine clinical management of patients with iron overload around the world.

### **By Order of the Board**

#### **Resonance Health Limited**

For further information please contact Resonance Health:

Liza Dunne  
Managing Director  
T: +61 8 9286 5300

E: [lizad@resonancehealth.com](mailto:lizad@resonancehealth.com)

Naomi Haydari  
Company Secretary  
T: +61 8 9286 5300

E: [naomih@resonancehealth.com](mailto:naomih@resonancehealth.com)

---

Resonance Health Ltd (ASX: RHT) ([www.resonancehealth.com](http://www.resonancehealth.com)) is a medical device company providing imaging core laboratory services for the quantitative analysis of medical images, with a subspecialty in the liver. Resonance Health's patented FerriScan technology provides a safe and accurate alternative for measuring liver iron concentration, and research continues into the development of new technology for the accurate assessment of liver fat and liver fibrosis.